The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 4, 2007, Pages 410-414

  Tönjes, Anke ^a   Stumvoll, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Diabetes; Pro12Ala; Review

Indexed keywords

ALANINE; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROLINE; TROGLITAZONE;

CLINICAL OBSERVATION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POPULATION RISK; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ALANINE; ALLELES; AMINO ACID SUBSTITUTION; DIABETES MELLITUS, TYPE 2; ENVIRONMENT; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; RISK FACTORS;

EID: 34250674020     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3281e389d9     Document Type: Review

References (57)

1. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12 ->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50:891-894.
2. Frederiksen L, Brodbaek K, Fenger M, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87:3989-3992.
3. Valve R, Sivenius K, Miettinen R, et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999; 84:3708-3712.
4. Ristow M, Muller-Wieland D, Pfeiffer A, et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339:953-959.
5. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402:880-883.
6. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
7. Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-182.
8. Willer CJ, Bonnycastle LL, Conneely KN, et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 2007; 56:256-264. This is a recent replication which demonstrates the Pro12Ala effect in a population-based case-control study in Finland.
9. McCarthy MI. Progress in defining the molecular basis of type 2 diabetes mellitus through susceptibility-gene identification. Hum Mol Genet 2004; 13(1):R33-R41.
10. Zeggini E, McCarthy MI. TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 2007; 50:1-4.
11. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345:971-980.
12. Shaat N, Groop L. Genetics of gestational diabetes mellitus. Curr Med Chem 2007; 14:569-583.
13. Shaat N, Ekelund M, Lernmark A, et al. Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus. Diabetologia 2004; 47:878-884.
14. Nelson TL, Fingerlin TE, Moss LK, et al. Association of the peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus varies by physical activity among non-Hispanic whites from Colorado. Metabolism 2007; 56:388-393. This is an association study in families with Type 2 diabetes from Colorado with a special focus on modification by diet or physical activity.
15. Franks PW, Luan J, Browne PO, et al. Does peroxisome proliferator-activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism 2004; 53:11-16.
16. Fornage M, Jacobs DR, Steffes MW, et al. Inverse effects of the PPAR (gamma)2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and whites. The CARDIA study. Metabolism 2005; 54:910-917.
17. Nemoto M, Sasaki T, Deeb SS, et al. Differential effect of PPARgamma2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans. Diabetes Res Clin Pract 2002; 57:131-137.
18. Radha V, Vimaleswaran KS, Babu HN, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity. Diabetes Care 2006; 29:1046-1051.
19. Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Prediabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006; 29:2489-2497. This meta-analysis focuses on the impact of Pro12Ala on glucose metabolism and BMI in nondiabetic subjects.
20. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333-1346.
21. Hartling SG, Roder ME, Dinesen B, Binder C. Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol 1996; 134:197-200.
22. Kahn SE, Bergman RN, Schwartz MW, et al. Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 1992; 262:518-523.
23. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003; 40:773-780.
24. Andrulionyte L, Peltola P, Chiasson JL, Laakso M. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2006; 55:2148-2152.
25. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004; 47:2176-2184.
26. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007; 92:1502-1509. This study examined whether the PPARγ Pro12Ala mutation affects progression from impaired glucose tolerance to diabetes, or responses to preventive interventions (lifestyle, metformin or troglitazone compared with a placebo).
27. Jaziri R, Lobbens S, Aubert R, et al. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006; 55:1157-1162. This was a prospective study to investigate the associations between PPARγ polymorphisms and insulin-resistance parameters and with the 6-year incidence of impaired fasting glucose or Type 2 diabetes in 3914 French whites from the DESIR (Data From an Epidemiological Study on the Insulin Resistance Syndrome) cohort.
28. Scaglioni S, Verduci E, Salvioni M, et al. PPAR-gamma2 Pro12Ala variant, insulin resistance and plasma long-chain polyunsaturated fatty acids in childhood obesity. Pediatr Res 2006; 60:485-489.
29. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92:386-395. This is a comprehensive overview of the role of PPARγ in adipose tissue.
30. Tschritter O, Fritsche A, Stefan N, et al. Increased insulin clearance in peroxisome proliferator-activated receptor gamma2 Pro12Ala. Metabolism 2003; 52:778-783.
31. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6:87-97.
32. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002; 51:2341-2347.
33. Stumvoll M, Wahl HG, Loblein K, et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001; 50:876-881.
34. Mousavinasab F, Tahtinen T, Jokelainen J, et al. Common polymorphisms in the PPARgamma2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men. Mol Genet Metab 2005; 84:344-348.
35. Radha V, Vimaleswaran KS, Babu S, et al. Lack of association between serum adiponectin levels and the Pro12Ala polymorphism in Asian Indians. Diabet Med 2007; 24:398-402.
36. Mousavinasab F, Tahtinen T, Jokelainen J, et al. Effect of the Pro12Ala polymorphism of the PPARg2 gene on serum adiponectin changes. Endocrine 2005; 27:307-309.
37. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947-953.
38. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108:1875-1881.
39. Stefan N, Stumvoll M, Vozarova B, et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26:3315-3319.
40. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094-2099.
41. Muller YL, Bogardus C, Beamer BA, et al. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003; 52:1864-1871.
42. Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004; 27:1365-1368.
43. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26:825-831.
44. Hansen L, Ekstrom CT, Tabanera YP, et al. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91:3446-3450. This is a study of impact of the Pro12Ala variant on side effects of thiazolidinediones and dual-acting PPARα/γ agonists.
45. Vaccaro O, Lapice E, Monticelli A, et al. Pro12Ala polymorphism of the PPAR{gamma}2 locus modulates the relationship between energy intake and body weight in type2 diabetic patients. Diabetes Care 2007 (epub ahead of print). This article gives an evaluation of modulation of the susceptibility to fat accumulation in response to habitual high-energy intake by Pro12Ala-variant PPARγ.
46. Meirhaeghe A, Boreham CA, Murray LJ, et al. A possible role for the PPARG Pro12Ala polymorphism in preterm birth. Diabetes 2007; 56:494-498. This is an analysis of two independent cross-sectional studies from Northern Ireland (n=382 and 620) to evaluate the role of the PPARγ Pro12Ala polymorphism in birth weight and duration of gestation.
47. Busjahn A, Knoblauch H, Faulhaber HD, et al. A region on chromosome 3 is linked to dizygotic twinning. Nat Genet 2000; 26:398-399.
48. Eriksson JG. Gene polymorphisms, size at birth, and the development of hypertension and type 2 diabetes. J Nutr 2007; 137:1063-1065.
49. Jaquet D, Tregouet DA, Godefroy T, et al. Combined effects of genetic and environmental factors on insulin resistance associated with reduced fetal growth. Diabetes 2002; 51:3473-3478.
50. Nassar BA, Rockwood K, Kirkland SA, et al. Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChE-K, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model. Clin Biochem 2006; 39:109-114.
51. Rhee EJ, Kwon CH, Lee WY, et al. No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects. Circ J 2007; 71:338-342.
52. Koivisto AM, Helisalmi S, Pihlajamaki J, et al. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population. Dement Geriatr Cogn Disord 2006; 22:449-453.
53. Scacchi R, Pinto A, Gambina G, et al. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res 2007; 1139:1-5. This is a study of the association of the Pro12Ala polymorphism with Alzheimer's disease.
54. Antoine HJ, Pall M, Trader BC, et al. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril 2007; 87:862-869.
55. Haap M, Machicao F, Stefan N, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes2005; 113:275-281.
56. Yilmaz M, Ergun MA, Karakoc A, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22:336-342.
57. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPARgamma. PPAR Res 2007; Epub ahead of print. This is a review of the literature on the genetics of polycystic ovary syndrome.